EN DE

Wellell Inc (4106) Fair Value & Analysis

Healthcare · TW · Market cap 2.5B TWD

WI Wellell Inc 4106 · TW
Price25.05 TWD
Fair Value26.41 TWD
Upside+5.4%
Quality66/100
Watch Wellell Inc for free, get notified when fair value or trend changes. Watch for free
Healthy Growth
Thin margins · 5.9% net margin
Low debt · generates free cash flow
Ranks above peers (12/14)
Narrow moat 38/100
Evidence: High Range 19.80 TWD – 33.01 TWD Share as image

Fair value as of: Jul 23, 2026

From 24 valuation models · updated 18 days ago

Share price +6.4% over the past month.

A solid business, currently priced close to our fair value.

What matters now

  • The price sits close to our fair value, market and models broadly agree here, little valuation tension.
  • Our model range runs from 19.80 TWD (bear) to 33.01 TWD (bull), base 26.41 TWD. The closer the price sits to the lower half, the larger the margin of safety.
  • Quality 66/100 (solid quality) with high evidence: the data supports the verdict.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

49.24 TWD 19.45 TWD Fair Value 26.41 TWD Mar 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 23, 2026.

How to read this chart

60‑month range 19.45 TWD – 49.24 TWD · fair‑value band 19.80 TWD – 33.01 TWD · the 25.05 TWD price screens below the 26.41 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 23, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Wellell Inc (4106) currently trades at 25.05 TWD, while our model-based Fair Value estimate is 26.41 TWD, implying the stock looks roughly 5.4% fairly valued today. The Quality Score stands at 66/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.

Over the trailing twelve months, Wellell Inc generated revenue of 2.4B TWD at a net margin of 5.9%. Revenue grew 4.8% year over year. It earns a return on equity of 5.9%. The balance sheet holds a net cash position of 536M TWD. Fundamentals as of Jul 23, 2026

Our scenario range runs from 19.80 TWD (bear case) to 33.01 TWD (bull case); at 25.05 TWD, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades near its 52-week high and 20% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside, at 5%, 4106 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Growth DCF 22.28 TWD 27.29 TWD 34.93 TWD 80
Residual Income 18.97 TWD 19.19 TWD 18.03 TWD 76
Rev-Margin DCF 20.36 TWD 26.58 TWD 33.85 TWD 74
All 24 models by family
DCF Models
FCF DCF 21.79 TWD 27.03 TWD 35.55 TWD 38
Owner Earnings 23.47 TWD 29.30 TWD 38.79 TWD 31
5Y Revenue Exit 20.36 TWD 26.33 TWD 34.39 TWD 39
5Y EBITDA Exit 26.70 TWD 37.23 TWD 50.18 TWD 41
5Y P/E Exit 23.15 TWD 31.11 TWD 39.89 TWD 38
10Y Revenue Exit 20.44 TWD 25.68 TWD 31.76 TWD 36
10Y EBITDA Exit 24.62 TWD 32.77 TWD 42.27 TWD 37
10Y P/E Exit 22.48 TWD 28.79 TWD 35.41 TWD 35
Earnings-Based
Graham-Dodd 8.16 TWD 15.19 TWD 18.84 TWD 54
EPV 16.41 TWD 17.92 TWD 19.22 TWD 59
Dividend Discount
Gordon GGM 7.03 TWD 9.31 TWD 11.57 TWD 70
DDM Multi-Stage 7.03 TWD 9.53 TWD 12.41 TWD 61
Multiples
P/E Multiple 19.80 TWD 26.41 TWD 33.01 TWD 63
P/S Multiple 15.30 TWD 20.41 TWD 25.51 TWD 58
P/B Multiple 15.30 TWD 20.41 TWD 25.51 TWD 55
EV/EBIT 25.90 TWD 32.25 TWD 38.61 TWD 53
EV/EBITDA 33.34 TWD 42.17 TWD 51.00 TWD 54
EV/Revenue 20.45 TWD 26.28 TWD 32.10 TWD 43
Asset-Based
NCAV (Graham) 12.54 TWD 16.80 TWD 25.07 TWD 50
Growth DCF
Growth DCF 22.28 TWD 27.29 TWD 34.93 TWD 80
Rev-Margin DCF 20.36 TWD 26.58 TWD 33.85 TWD 74
Economic Profit
Residual Income 18.97 TWD 19.19 TWD 18.03 TWD 76
ROIC Compounder 16.41 TWD 17.92 TWD 19.22 TWD 72
Growth Earnings
Growth-Adj P/E 14.07 TWD 20.10 TWD 26.14 TWD 68

Widest divergence: DCF Models (28.79 TWD) versus Dividend Discount (9.31 TWD). Highest evidence: Growth DCF (80).

Notify me when 4106 reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) 2.4B TWD
Revenue growth (YoY) +4.8%
Net margin 5.9%
Return on equity 5.9%
Free cash flow 155M TWD FY2025
P/E ratio 19.6
More key figures
Operating margin 10.0%
EPS (TTM) 1.19 TWD
EPS growth (YoY) +101%
Net cash 536M TWD FY2025

Figures from reported company fundamentals · as of Jul 23, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 66/100

Of which business quality 66 · Market factors (momentum, volatility) 68

Profitability 42
Margins and returns on capital today
Quality Growth 45
Are margins and returns improving?
Cashflow 56
Earnings quality: real cash, not paper profit
Fin. Strength 90
Balance sheet, leverage, solvency risk
Investment 92
Disciplined investing over empire-building
Low Volatility 98
Calm price path (market factor)
Momentum 51
Price trend over the last 3–12 months (market factor)
52W Momentum 64
Distance to the 52-week high (market factor)
Net Issuance 81
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Wellell Inc. engages in the manufacture and sale of medical supplies in Europe, the United States, Asia, and internationally. The company offers support surface systems, respiratory therapy devices, and other products.

Full company description

Wellell Inc. engages in the manufacture and sale of medical supplies in Europe, the United States, Asia, and internationally. The company offers support surface systems, respiratory therapy devices, and other products. It also provides pressure relief mattress; sleep apnea such as auto-adjusting pressure; sleepwell; compression therapy; and pressure relief seating products. In addition, the company offers pressure injury prevention, and obstructive sleep apnea solutions. The company was founded in 1990 and is based in New Taipei City, Taiwan.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Wellell Inc reported revenue of 2.4B TWD in FY2025 versus 2.4B TWD in FY2021, a compound +0.3%/yr. Reported net income was 121M TWD in FY2025, compounding +4.3%/yr from FY2021.

Growth Quality 62/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Latest Revenue (FY 2025)
2.4B TWD
Latest YoY
+0.7%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−3.4%
Avg. growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+3.7%
Avg. growth/yr (23Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+4.3%
Revenue +0.3%/yr
FY21 2.4B TWD
FY22 2.7B TWD
FY23 2.6B TWD
FY24 2.4B TWD
FY25 2.4B TWD
Net income +4.3%/yr
FY21 102M TWD
FY22 161M TWD
FY23 152M TWD
FY24 115M TWD
FY25 121M TWD
Character of growth · EPS growth decomposed (2014-2025) −4.1 % p.a.
Revenue per share −0.2 pp

of which total revenue +1.9 pp · buybacks/dilution −2.1 pp

EBIT margin −4.2 pp
Tax rate −0.3 pp
Residual (interest, one-offs) +0.6 pp

Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).

Watch 4106: get an alert when its fair value changes →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Wellell Inc Fair Value". https://www.fairvalue-calculator.com/stock/4106

Peer Group

Medical Devices · 352 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 66 · Top 25%
Fair Value upside +5% · Top 25%
Return on equity (TTM) 6% · Above median
Return on assets 4% · Above median
Net margin (TTM) 6% · Above median
Operating margin (TTM) 10% · Above median
Revenue growth 5% · Below median
Dividend yield (TTM) 0.0% · Bottom 25%
Debt / equity 0.04× · Lower than median

Valuation Multiples vs Medical Devices median · lower = cheaper

P/E (TTM) 20.7× · Cheaper than median
P/B 0.98× · Cheaper than median
P/S (TTM) 1.02× · Cheaper than median
P/FCF 0.5× · Cheaper than 75% of peers
EV/EBITDA 6.3× · Cheaper than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 41 · sector 0
FUTURE 24 · sector 29
PAST 24 · sector 8
HEALTH 98 · sector 97
DIVIDEND 0 · sector 38

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 23, 2026).

Stock Price Fair Value vs Fair Value
Abbott Laboratories, ABT $100.68 $74.79 -26%
Stryker Corporation SYK $316.44 $186.28 -41%
Medtronic plc MDT $83.56 $65.57 -22%
Boston Scientific Corporation BSX $43.04 $38.44 -11%
Edwards Lifesciences Corporation EW $85.73 $41.02 -52%
Siemens Healthineers AG SHL €34.59 €33.87 -2%
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥149.43 ¥147.63 -1%
Shanghai United Imaging Healthcare Co 688271 ¥109.00 ¥43.60 -60%
Demant A/S DEMANT kr 276.60 kr 161.17 -42%
Getinge AB GETIB kr 206.80 kr 192.14 -7%

Compare Wellell Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Wellell Inc (4106) overvalued or undervalued?
As of Jul 23, 2026, our model estimates a fair value of 26.41 TWD versus a price of 25.05 TWD, about +5% (fairly valued).
What is the fair value of 4106?
Our model-based fair value for Wellell Inc is 26.41 TWD (as of Jul 23, 2026), built from audited fundamentals. The current price is 25.05 TWD.
What is the quality score of 4106?
Wellell Inc has a Quality Score of 66/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Wellell Inc (4106)?
Wellell Inc reported trailing-twelve-month revenue of about 2.4B TWD (latest available figure, as of Jul 23, 2026).
What is the net profit margin of 4106?
The net profit margin of Wellell Inc is about 5.9%, meaning it keeps roughly 5.9% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Wellell Inc and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.